STRATEC SE
STRATEC continues growth in 2017
DGAP-News: STRATEC Biomedical AG / Key word(s): Quarterly / Interim Statement/Quarter Results STRATEC continues growth in 2017 – Sales of EUR 49.5 million in Q1/2017 (+58.6%; Q1/2016: EUR 31.2 million) Birkenfeld, May 4, 2017 STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard) today announced its financial results for the period from January 1, 2017 through to March 31, 2017 with the publication of its Quarterly Statement Q1|2017.
bps = basis points Business performance The Group generated adjusted EBIT of EUR 6.9 million in the first quarter of 2017. The adjusted EBIT margin came to 13.9%, as against 14.5% in the equivalent period in the previous year. This temporary reduction is particularly attributable to the high share of overall sales due to lower-margin development services and the dilution in the margin due to the new subsidiaries, as well as to a compensation component included under personnel expenses for stock appreciation rights, which took material effect for the first time in the first quarter. This resulted in consolidated net income of EUR 5.4 million (+56.8%; previous year: EUR 3.4 million). Earnings per share amounted to EUR 0.45 (+55.2%, previous year: EUR 0.29). These earnings figures have been adjusted to exclude purchase price allocation-related amortization resulting from the acquisitions of Diatron and STRATEC Consumables and one-off items resulting from transaction activities and associated restructuring expenses. Development in personnel To deal with large numbers of development projects, STRATEC continues to seek qualified personnel and expects to report rising employee totals in the quarters ahead, as well. Projects and other developments The STRATEC platforms in development are already the object of specific negotiations with partners with regard to further development projects and resultant cooperations. The company plans to present initial joint system solutions at the AACC fair to be held in San Diego, US, in August. STRATEC sees these projects as providing an additional basis for its future growth and further diversification. The acquisitions of the new companies have already impacted positively on the performance of the STRATEC Group in the current financial year, especially in the form of project negotiations and contract agreements. STRATEC will continue to focus in the current year on achieving major development milestones and market launches. Financial forecast 2017 Annual General Meeting Quarterly Statement Conference call and audio webcast The access information (telephone number, password + individual PIN) will be provided following brief registration at the following link: www.stratec.com/registration The call may also be followed as an audio webcast at www.stratec.com/audiowebcast20170504 (brief registration required). Please note that it is not possible to submit any questions via the audio webcast. About STRATEC The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange. Further information can be obtained from:
04.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | STRATEC Biomedical AG |
Gewerbestr. 37 | |
75217 Birkenfeld | |
Germany | |
Phone: | +49 (0)7082 7916 0 |
Fax: | +49 (0)7082 7916 999 |
E-mail: | info@stratec.com |
Internet: | www.stratec.com |
ISIN: | DE000STRA555 |
WKN: | STRA55 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |